Ocugenix is a therapeutics company founded with the mission to develop innovative cancer immunotherapy drugs specifically designed to treat eye diseases. The company's vision is to leverage the body's natural healing mechanisms to combat conditions such as Wet Macular Degeneration, Geographic Atrophy, and Proliferative Diabetic Retinopathy. Ocugenix focuses on creating treatments that address drug-resistant bacteria, providing doctors with effective tools for cancer-related eye treatments. They are also working on an ocular indication for Dry Eye, which is currently in the IND-enabling stage.

Ocugenix has made significant strides in the field of ophthalmology by being the only company to harness the body's natural processes for treating angio-fibrotic eye diseases. The company is preparing to begin Phase II programs for its key indications. Notable affiliated individuals and investors have not been disclosed, but the company's innovative approach and progress in clinical stages highlight its potential impact on eye disease treatment. Ocugenix's advancements promise to bring new hope to patients suffering from these challenging conditions.